Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial
The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is associated with a decrease in viral load of SARS-CoV-2 compared with placebo.Trial designFLARE is a phase IIA randomised, double-blind, 2x2 factorial placebo-controlled, interventional trial.ParticipantsThis trial is being conducted in the United Kingdom, with Royal Free Hospital, London as the lead site. Participants are non-hospitalised adults with highly suspected COVID-19 within the first 5 days of symptom onset, or wh...
Source: Trials - March 8, 2021 Category: Research Source Type: clinical trials

HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Conditions:   Hepatitis C Virus Infection;   Hepatitis C Virus Infection, Response to Therapy of;   Human Immunodeficiency Virus (HIV) Coinfection Intervention:   Sponsor:   National Taiwan University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2021 Category: Research Source Type: clinical trials

COVID-19 Immunologic Antiviral Therapy With Omalizumab
Condition:   Covid19 Interventions:   Biological: Omalizumab;   Other: Placebo Sponsor:   McGill University Health Centre/Research Institute of the McGill University Health Centre Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials